Reports
Reports
Sale
The global human papillomavirus (HPV) vaccine market attained a value of nearly USD 5.22 billion in 2023. The market is estimated to grow in the forecast period of 2024-2032 at a CAGR of 11.60% to reach about USD 13.96 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The human papillomavirus (HPV) vaccine market in North America is expected to witness significant growth during the forecast period on account of the increasing awareness regarding human papillomavirus among the masses and the surging association of human papillomavirus with cervical cancer. The increasing incidences of human papillomavirus (HPV) associated cancers and the rising focus to prevent these infections are further driving the market growth of human papillomavirus (HPV) vaccine. Moreover, the developing healthcare infrastructure and the growing healthcare expenditure in developing countries are likely to create healthy growth opportunities for the market players in the region. In the United States, human papillomavirus is one of the most common sexually transmitted infections, which is likely to propel the market for HPV vaccine over the forecast period.
Human papillomavirus (HPV) vaccine is a vaccination that is typically administered in children at age 11-12 years and protects them from certain cancers. It also prevents vaginal and vulvar cancer. Additionally, the vaccine can prevent anal cancers, genital warts, and mouth, throat, neck, and head cancers in men and women. Gardasil 9 is an HPV vaccine approved by the U.S. Food and Drug Administration and can be used for both females and males.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The market for human papillomavirus (HPV) vaccine, by type, is divided into:
The market can be broadly categorised on the basis of distribution channel segments into:
Based on Indication, the market is segmented into:
By diseases, the market is segmented into:
The EMR report looks into the regional markets of human papillomavirus (HPV) vaccine like Latin America, North America, Europe, the Asia Pacific, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The human papillomavirus (HPV) vaccine market is likely to witness growth during the forecast period on account of the rising cases of human papillomavirus diseases. The surging initiatives by organisations and governments for early screening and vaccination of HPV, coupled with the emergence of new HPV vaccines like Gardasil 9, are expected to drive the market growth of human papillomavirus (HPV) vaccine. The growing incidences of HPV-related malignancies in the oropharynx, anal, and genital areas, coupled with an upsurge in demand for HPV vaccinations to help reduce infections, are expected to bolster the market for human papillomavirus (HPV) vaccine. The increasing R&D activities to prevent and control the spread of such diseases through preventative immunisations are further expected to fuel the market for the human papillomavirus (HPV) vaccine.
The report presents a detailed analysis of the following key players in the global human papillomavirus (HPV) vaccine market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
The comprehensive report looks into the macro and micro aspects of the market. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Type |
|
Breakup by Distribution Channel |
|
Breakup by Indication |
|
Breakup by Diseases |
|
Breakup by Region |
|
Market Dynamics |
|
Competitive Landscape |
|
Companies Covered |
|
Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Application
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Market Snapshot
6.1 Global
6.2 Regional
7 Opportunities and Challenges in the Market
8 Global Human Papillomavirus (HPV) Vaccine Market Analysis
8.1 Key Industry Highlights
8.2 Global Human Papillomavirus (HPV) Vaccine Historical Market (2018-2023)
8.3 Global Human Papillomavirus (HPV) Vaccine Market Forecast (2024-2032)
8.4 Global Human Papillomavirus (HPV) Vaccine Market by Type
8.4.1 Bivalent
8.4.1.1 Historical Trend (2018-2023)
8.4.1.2 Forecast Trend (2024-2032)
8.4.2 Polyvalent
8.4.2.1 Historical Trend (2018-2023)
8.4.2.2 Forecast Trend (2024-2032)
8.5 Global Human Papillomavirus (HPV) Vaccine Market by Distribution Channel
8.5.1 Hospital and Retail Pharmacies
8.5.1.1 Historical Trend (2018-2023)
8.5.1.2 Forecast Trend (2024-2032)
8.5.2 Government Suppliers
8.5.2.1 Historical Trend (2018-2023)
8.5.2.2 Forecast Trend (2024-2032)
8.5.3 Others
8.6 Global Human Papillomavirus (HPV) Vaccine Market by Indication
8.6.1 Genital Warts
8.6.1.1 Historical Trend (2018-2023)
8.6.1.2 Forecast Trend (2024-2032)
8.6.2 HPV Associated Cancer
8.6.2.1 Historical Trend (2018-2023)
8.6.2.2 Forecast Trend (2024-2032)
8.7 Global Human Papillomavirus (HPV) Vaccine Market by Diseases
8.7.1 Systemic Human Papillomavirus Vaccine
8.7.1.1 Historical Trend (2018-2023)
8.7.1.2 Forecast Trend (2024-2032)
8.7.1.3 Breakup by Type
8.7.1.3.1 Systemic Lupus Erythematosus
8.7.1.3.2 Ankylosing Spondylitis
8.7.1.3.3 Rheumatoid Arthritis
8.7.1.3.4 Others
8.7.2 Localised Human Papillomavirus Vaccine
8.7.2.1 Historical Trend (2018-2023)
8.7.2.2 Forecast Trend (2024-2032)
8.7.2.3 Breakup by Type
8.7.2.3.1 Inflammatory Bowel Disease
8.7.2.3.2 Type 1 Diabetes
8.7.2.3.3 Thyroid
8.7.2.3.4 Others
8.8 Global Human Papillomavirus (HPV) Vaccine Market by Region
8.8.1 North America
8.8.1.1 Historical Trend (2018-2023)
8.8.1.2 Forecast Trend (2024-2032)
8.8.2 Europe
8.8.2.1 Historical Trend (2018-2023)
8.8.2.2 Forecast Trend (2024-2032)
8.8.3 Asia Pacific
8.8.3.1 Historical Trend (2018-2023)
8.8.3.2 Forecast Trend (2024-2032)
8.8.4 Latin America
8.8.4.1 Historical Trend (2018-2023)
8.8.4.2 Forecast Trend (2024-2032)
8.8.5 Middle East and Africa
8.8.5.1 Historical Trend (2018-2023)
8.8.5.2 Forecast Trend (2024-2032)
9 North America Human Papillomavirus (HPV) Vaccine Market Analysis
9.1 United States of America
9.1.1 Historical Trend (2018-2023)
9.1.2 Forecast Trend (2024-2032)
9.2 Canada
9.2.1 Historical Trend (2018-2023)
9.2.2 Forecast Trend (2024-2032)
10 Europe Human Papillomavirus (HPV) Vaccine Market Analysis
10.1 United Kingdom
10.1.1 Historical Trend (2018-2023)
10.1.2 Forecast Trend (2024-2032)
10.2 Germany
10.2.1 Historical Trend (2018-2023)
10.2.2 Forecast Trend (2024-2032)
10.3 France
10.3.1 Historical Trend (2018-2023)
10.3.2 Forecast Trend (2024-2032)
10.4 Italy
10.4.1 Historical Trend (2018-2023)
10.4.2 Forecast Trend (2024-2032)
10.5 Others
11 Asia Pacific Human Papillomavirus (HPV) Vaccine Market Analysis
11.1 China
11.1.1 Historical Trend (2018-2023)
11.1.2 Forecast Trend (2024-2032)
11.2 Japan
11.2.1 Historical Trend (2018-2023)
11.2.2 Forecast Trend (2024-2032)
11.3 India
11.3.1 Historical Trend (2018-2023)
11.3.2 Forecast Trend (2024-2032)
11.4 ASEAN
11.4.1 Historical Trend (2018-2023)
11.4.2 Forecast Trend (2024-2032)
11.5 Australia
11.5.1 Historical Trend (2018-2023)
11.5.2 Forecast Trend (2024-2032)
11.6 Others
12 Latin America Human Papillomavirus (HPV) Vaccine Market Analysis
12.1 Brazil
12.1.1 Historical Trend (2018-2023)
12.1.2 Forecast Trend (2024-2032)
12.2 Argentina
12.2.1 Historical Trend (2018-2023)
12.2.2 Forecast Trend (2024-2032)
12.3 Mexico
12.3.1 Historical Trend (2018-2023)
12.3.2 Forecast Trend (2024-2032)
12.4 Others
13 Middle East and Africa Human Papillomavirus (HPV) Vaccine Market Analysis
13.1 Saudi Arabia
13.1.1 Historical Trend (2018-2023)
13.1.2 Forecast Trend (2024-2032)
13.2 United Arab Emirates
13.2.1 Historical Trend (2018-2023)
13.2.2 Forecast Trend (2024-2032)
13.3 Nigeria
13.3.1 Historical Trend (2018-2023)
13.3.2 Forecast Trend (2024-2032)
13.4 South Africa
13.4.1 Historical Trend (2018-2023)
13.4.2 Forecast Trend (2024-2032)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter’s Five Forces Analysis
14.2.1 Supplier’s Power
14.2.2 Buyer’s Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
14.3 Key Indicators for Demand
14.4 Key Indicators for Price
15 Value Chain Analysis
16 Price Analysis
17 Competitive Landscape
17.1 Market Structure
17.2 Company Profiles
17.2.1 Merck & Co., Inc.
17.2.1.1 Company Overview
17.2.1.2 Product Portfolio
17.2.1.3 Demographic Reach and Achievements
17.2.1.4 Certifications
17.2.2 GlaxoSmithKline plc.
17.2.2.1 Company Overview
17.2.2.2 Product Portfolio
17.2.2.3 Demographic Reach and Achievements
17.2.2.4 Certifications
17.2.3 Johnson & Johnson Services, Inc.
17.2.3.1 Company Overview
17.2.3.2 Product Portfolio
17.2.3.3 Demographic Reach and Achievements
17.2.3.4 Certifications
17.2.4 Serum Institute of India Pvt. Ltd.
17.2.4.1 Company Overview
17.2.4.2 Product Portfolio
17.2.4.3 Demographic Reach and Achievements
17.2.4.4 Certifications
17.2.5 Bavarian Nordic A/S
17.2.5.1 Company Overview
17.2.5.2 Product Portfolio
17.2.5.3 Demographic Reach and Achievements
17.2.5.4 Certifications
17.2.6 Others
18 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Global Human Papillomavirus (HPV) Vaccine Market: Key Industry Highlights, 2018 and 2032
2. Global Human Papillomavirus (HPV) Vaccine Historical Market: Breakup by Type (USD Million), 2018-2023
3. Global Human Papillomavirus (HPV) Vaccine Market Forecast: Breakup by Type (USD Million), 2024-2032
4. Global Human Papillomavirus (HPV) Vaccine Historical Market: Breakup by Distribution Channel (USD Million), 2018-2023
5. Global Human Papillomavirus (HPV) Vaccine Market Forecast: Breakup by Distribution Channel (USD Million), 2024-2032
6. Global Human Papillomavirus (HPV) Vaccine Historical Market: Breakup by Indication (USD Million), 2018-2023
7. Global Human Papillomavirus (HPV) Vaccine Market Forecast: Breakup by Indication (USD Million), 2024-2032
8. Global Human Papillomavirus (HPV) Vaccine Historical Market: Breakup by Diseases (USD Million), 2018-2023
9. Global Human Papillomavirus (HPV) Vaccine Market Forecast: Breakup by Diseases (USD Million), 2024-2032
10. Global Human Papillomavirus (HPV) Vaccine Historical Market: Breakup by Region (USD Million), 2018-2023
11. Global Human Papillomavirus (HPV) Vaccine Market Forecast: Breakup by Region (USD Million), 2024-2032
12. North America Human Papillomavirus (HPV) Vaccine Historical Market: Breakup by Country (USD Million), 2018-2023
13. North America Human Papillomavirus (HPV) Vaccine Market Forecast: Breakup by Country (USD Million), 2024-2032
14. Europe Human Papillomavirus (HPV) Vaccine Historical Market: Breakup by Country (USD Million), 2018-2023
15. Europe Human Papillomavirus (HPV) Vaccine Market Forecast: Breakup by Country (USD Million), 2024-2032
16. Asia Pacific Human Papillomavirus (HPV) Vaccine Historical Market: Breakup by Country (USD Million), 2018-2023
17. Asia Pacific Human Papillomavirus (HPV) Vaccine Market Forecast: Breakup by Country (USD Million), 2024-2032
18. Latin America Human Papillomavirus (HPV) Vaccine Historical Market: Breakup by Country (USD Million), 2018-2023
19. Latin America Human Papillomavirus (HPV) Vaccine Market Forecast: Breakup by Country (USD Million), 2024-2032
20. Middle East and Africa Human Papillomavirus (HPV) Vaccine Historical Market: Breakup by Country (USD Million), 2018-2023
21. Middle East and Africa Human Papillomavirus (HPV) Vaccine Market Forecast: Breakup by Country (USD Million), 2024-2032
22. North America Historical Price Trends and Forecast 2018-2028
23. Europe Historical Price Trends and Forecast 2018-2028
24. Asia Pacific Historical Price Trends and Forecast 2018-2028
25. Latin America Historical Price Trends and Forecast 2018-2028
26. Middle East and Africa Historical Price Trends and Forecast 2018-2028
27. Global Human Papillomavirus (HPV) Vaccine Market Structure
In 2023, the global human papillomavirus (HPV) vaccine market attained a value of nearly USD 5.22 billion.
The market is assessed to grow at a CAGR of 11.60% between 2024 and 2032.
The market is estimated to witness healthy growth in the forecast period of 2024-2032 to reach almost USD 13.96 billion by 2032.
The major market drivers are the growing awareness regarding human papillomavirus, the rising incidences of HPV-associated cancers, the increasing healthcare facilities.
The key market trends guiding the growth of the market include the introduction of various government initiatives to boost HPV vaccination, the growing incidences of HPV-related malignancies, and developing healthcare infrastructure.
The major regions in the market are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
The various types of human papillomavirus virus (HPV) vaccine in the market are bivalent and polyvalent.
The different distribution channel of human papillomavirus (HPV) vaccine include hospital and retail pharmacies and government suppliers, among others.
The significant indications of human papillomavirus (HPV) vaccine in the market are genital warts and HPV associated cancer.
The major diseases of human papillomavirus (HPV) vaccine, include systemic human papillomavirus vaccine and localised human papillomavirus vaccine.
The major players in the market are Merck & Co., Inc., GlaxoSmithKline plc., Johnson & Johnson Services, Inc., Serum Institute of India Pvt. Ltd., and Bavarian Nordic A/S, among others.
The global human papillomavirus (HPV) vaccine market attained a value of nearly USD 5.22 billion in 2023, driven by the increasing awareness about human papillomavirus. Aided by the growing demand for human papillomavirus (HPV) vaccines, the market is expected to witness further growth in the forecast period of 2024-2032, growing at a CAGR of 11.60%. The market is estimated to reach about USD 13.96 billion by 2032.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the market. The market for human papillomavirus (HPV) vaccine, by type, is divided into bivalent and polyvalent. On the basis of distribution channel, the market is segmented into hospital and retail pharmacies and government suppliers, among others. Based on indications, the market is bifurcated into genital warts and HPV associated cancer. On the basis of diseases, the market is classified into systemic human papillomavirus vaccine and localised human papillomavirus vaccine. The major regional markets for human papillomavirus (HPV) vaccine are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Merck & Co., Inc., GlaxoSmithKline plc., Johnson & Johnson Services, Inc., Serum Institute of India Pvt. Ltd., and Bavarian Nordic A/S, among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.